Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
Respiratory Tract Infections
Guadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2018;124:325-34. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency